August 2026– date –
-
Real-World Data Reveals 83.9% Treatment Failure Rate in Second-Line Diffuse Large B-Cell Lymphoma Despite New Therapies; CAR-T Patients Show 26.4-Month Median OS
MDNewsline Unknown Overview Despite the introduction of novel therapies, real-world treatment patterns for Diffuse Large B-Cell Lymphoma (DLBCL) continue to face challenges with poor patient prognosis and high treatment failure rates in ... -
Vertex Pharmaceuticals Secures FDA IND Approval for iPSC-Derived Type 1 Diabetes Therapies, Boosts 2026 Revenue Forecast
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced robust Q2 2026 financial results and significantly raised its full-year revenue guidance, propelled by key pipeline advancements. The company secured FDA Investigationa... -
EUDA Health Partners with GO POSB and SIIT to Accelerate Off-the-Shelf iPSC Cell Therapy for Oncology and Wellness
Stock Titan Singapore Overview EUDA Health announced a collaboration to integrate GO POSB's iPSC platform with SIIT's NK and NK-TCR cell engineering capabilities, aiming to advance off-the-shelf cell therapy programs in oncology and well... -
IMBIOORG2026 Conference Highlights Latest Trends and Partnerships in 3D Bioprinting and Organ Regeneration
InSciTech Summits International Overview The IMBIOORG2026 international conference will showcase cutting-edge research, innovations, and transformative applications in 3D bioprinting, tissue engineering, regenerative medicine, and organ ... -
Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access
Bioprocessing Summit Europe International Overview The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variabil... -
Allogeneic CAR T-Cells: The Off-the-Shelf Revolution in Cancer Immunotherapy Manufacturing
Liv Hospital Turkey Overview Autologous CAR T-cell therapies face significant hurdles in scalability and turnaround time, limiting their broad accessibility. The industry is rapidly shifting towards off-the-shelf allogeneic CAR T-cells, ... -
U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designations: 168 Publicly Announced by 2026, Accelerating Transformative Therapies in Oncology and Rare Diseases
BioInformant USA Overview According to BioInformant, as of August 2026, the U.S. FDA has publicly announced 168 Regenerative Medicine Advanced Therapy (RMAT) designations. These designations are granted to cell and gene therapy products ... -
Advances in 3D Bioprinting for Organoid Construction: Enhancing Physiological Relevance and Promoting Diverse Biomedical Applications
PMC (NIH) International Overview A comprehensive review article highlights recent advancements in 3D bioprinting technology for organoid construction. This technique overcomes challenges of traditional organoid culture methods by precise... -
Intellia Therapeutics Reports Positive Phase 3 HAELO Data for lonvo-z in HAE and Resumes Nex-z ATTR Phase 3 Enrollment
Intellia Therapeutics USA Overview Intellia Therapeutics announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), published in the New England Journal of Medicine. The company anticipates FDA Biologics L... -
Capra Biosciences Boosts Domestic Manufacturing of Essential Medicines with Continued HHS Support, Strengthening Biopharmaceutical Supply Chain Resilience
BioSpace USA Overview Capra Biosciences announced plans to strengthen its domestic manufacturing capabilities for essential medicines with ongoing financial support from the U.S. Department of Health and Human Services (HHS). This initia...
